Return to CBI Antibody Core Home Page
  Return to human list
    Return to human ( Homo sapiens ) list


human ( Homo sapiens )
HPS-6


Links to multiple antibodies on this page for HPS-6:
HPS-6
HPS-6


Western result: +
control
HPS-6
A1129b
(fragment)

32.2 kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (recombinant fusion protein containing a His tag). The negative control lane is the same except it contains ~50ng to 100 ng of a recombinant fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used.

Antibody Name/Abbreviation: HPS-6
CBI Antibody Core Code: A1129b

"Lot" Number: 1 Position: 20 (234-253)
% Identical Homology of Target to Mouse Protein: 85% (NP_789742.1| Hermansky-Pudlak syndrome 6; ruby eye)
Molecular Weight of GST-fusion: 32.2 KDa

Target sequence used to make this antibody:
GLSYSKSLNPGRGDTWDFRT






Antibody Name/Abbreviation: HPS-6
CBI Antibody Core Code: A1129a

"Lot" Number: 1 Position: 100 (525-624)
% Identical Homology of Target to Mouse Protein: 54% (NP_789742.1| Hermansky-Pudlak syndrome 6; ruby eye)
Molecular Weight of fusion protein: 25 KDa

Target sequence used to make this antibody:
LQLQLDGNGKLRSQAPPDVWKKVLGGITAGKEPPNGILPP
FELLCQCLCQLEPRWLPPFVELAQQQGGPGWGAGGPGLPL
YRRALAVLGEEGTRPEALEL






Sequence Name: HPS-6
Full name: Hermansky-Pudlak syndrome-6
UniGene Number: N.A.
Accession Number: NP_079023.2
Source organism: human ( Homo sapiens )
Full length size (aa): 775
NCBI information page: click here

Full length sequence:
mkrsgtlrllsdlsafggaarlrelvagdsavrvrgspdgrhllllrppg
avapqllvasrgpgaelerawpagqpspldafflpwparpalvlvwesgl
aevwgagvgpgwrplqstelcpgggarvvavaalrgrlvwceerqaraeg
psgspaaafshcvcvrtlepsgeastslgrthvllhhcpafgllascrql
flvptattwpgvahvlliwspgkgkvmvaaprlglsyskslnpgrgdtwd
frtllrglpgllspreplavhtwaptpqglllldfggtvsllqshggtra
vgtlqeapvgpwgsaalgtfqgtlacvlgstlelldmgsgqllerkvlst
drvhlleppapgmedeeeletrgnlrllsalglfcvgweapqgvelpsak
dlvfeeacgyyqrrslrgaqltpeelrhsstfrapqalasilqghlppsa
lltmlrtelrdyrgleqlkaqlvagddeeagwtelaeqevarllrtelig
dqlaqlntvfqalptaawgatlralqlqldgngklrsqappdvwkkvlgg
itagkeppngilppfellcqclcqleprwlppfvelaqqqggpgwgaggp
glplyrralavlgeegtrpealelelllssgrpkavlqavgqlvqkeqwd
raldaglalgpsspllrseifklllaefaqhrrldahlpllcrlcppela
paelllllrtylpdevgpptpfpepgaeppltvgllkalleqtgaqgwls
gpvlspyedilwdpstppptpprdl





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.